Drug Trial Radar · NCT04796428
GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial
Last checked: Nov 19, 2026Latest source record: Mar 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,167
Planned (sponsor's estimate)
Start
Jun 30, 2021
Primary completion
Dec 31, 2023
Study completion Dec 31, 2023
Sponsor
- Lead sponsor
- Center for Outcomes Research and Clinical Epidemiology, ItalyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Italian Society of Diabetology
- First posted
- Mar 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 70 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Three SGLT2i were commercially available in Italy at the time the trial was designed: canagliflozin, dapagliflozin, and empagliflozin. Preliminary evidence suggests that the higher dose canagliflozin (300 mg/day) might exert a stronger glucose-lowering effect than dapagliflozin or empagliflozin. The clinical relevance of this putative difference is however unknown. On the other side, the use of canagliflozin, but not empagliflozin and dapagliflozin, has been associated with an increased risk of some adverse events, namely bone fractures and lower limb amputations. Currently, the available information on the efficacy and safety of SGLT2i in elderly (70+ years) patients with type 2 diabetes are is very scant. Thus, a compelling need now exists of comparing efficacy and safety of the commercially available SGLT2i in a population of frail patients at high risk of cardiovascular and renal diseases.
Conditions
- Diabetes Mellitus, Type 2
Interventions
CanagliflozinDrug
Canagliflozin If the patient is already on metformin, the fixed combination Canagliflozin / Metformin can be used.
DapagliflozinDrug
Dapagliflozin If the patient is already on metformin, the fixed combination dapagliflozin / metformin can be used. If the patient is already on a DPP-4 inhibitor, the fixed dose combination dapagliflozin / saxagliptin can be used.
EmpagliflozinDrug
If the patient is already on metformin, the fixed combination empagliflozin / metformin can be used. If the patient is already on a DPP-4 inhibitor, the fixed dose combination empagliflozin / linagliptin can be used.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary ObjectiveTime frame: Up to 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.